Recommendation of the President – validity of granting marketing authorizations for medicinal products containing the active substance nadolol
On 17 July 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No.91/2025 on the validity of granting marketing authorizations for medicinal products containing the active substance nadolol for the following indications: long QT syndrome, polymorphic ventricular tachycardia, hypertension, hypertrophic cardiomyopathy, Andersen-Tawila syndrome